# US 2003/0228634 A1 · Expression vectors encoding epitopes of target-associated antigens and methods for their design

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228634 A1
- Document ID: US20030228634A1
- Status: Published application
- Kind: A1
- Application number: 10/292,413
- Filed: 2002-11-07
- Published: 2003-12-11
- Earliest claimed: 2001-11-07
- Assignees: MannKind Corporation
- Inventors: John J.L. Simard; David C. Diamond; Zhiyong Qiu; Xiang-Dong Lei
- Web page: https://patentgrep.com/patent/US20030228634A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4269: {NY-ESO}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C12N 15/85: for animal cells
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/6075: {Viral proteins}
- C07K 2319/00: Fusion polypeptide
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2840/203: having an IRES
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

## Claims

### Claim 1

A method of identifying a polypeptide suitable for epitope liberation, the method comprising the steps of:
identifying an epitope of interest;
providing a substrate polypeptide sequence comprising the epitope, wherein the substrate polypeptide permits processing by a proteasome;
contacting the substrate polypeptide with a composition comprising the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and
assaying for liberation of the epitope.

### Claim 2 (depends on 1)

The method of claim 1, wherein the epitope is embedded in the substrate polypeptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the epitope is a housekeeping epitope.

### Claim 4 (depends on 1)

The method of claim 1, wherein the substrate polypeptide is a synthetic peptide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the substrate polypeptide is a fusion protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein the contacting step comprises immunization with the substrate polypeptide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the substrate polypeptide is encoded by a polynucleotide.

### Claim 8 (depends on 7)

The method of claim 7, wherein the contacting step comprises immunization with a vector comprising the polynucleotide.

### Claim 9 (depends on 7)

The method of claim 7, wherein the contacting step comprises transforming a cell with a vector comprising the polynucleotide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the proteasome processing takes place in vitro.

### Claim 11 (depends on 1)

The method of claim 1, wherein the assaying step consists of a technique selected from the group consisting of mass spectrometry, N-terminal pool sequencing, and HPLC.

### Claim 12 (depends on 1)

The method of claim 1, wherein the assaying step comprises a T cell target recognition assay.

### Claim 13 (depends on 1)

The method of claim 1, wherein the substrate polypeptide further comprises an array of additional epitopes.

### Claim 14 (depends on 13)

The method of claim 13, wherein the array comprises a housekeeping and an immune epitope.

### Claim 15 (depends on 1)

The method of claim 1, wherein the substrate polypeptide further comprises an array of epitopes and epitope clusters.

### Claim 16 (depends on 1)

The method of claim 1, wherein the proteasome is an immune proteasome.

### Claim 17

A vector comprising a housekeeping epitope expression cassette, wherein the housekeeping epitope is derived from a target-associated antigen, and wherein the housekeeping epitope is liberatable from a translation product of the cassette by immunoproteasome processing.

### Claim 18 (depends on 17)

The vector of claim 17, wherein the expression cassette encodes an array of two or more epitopes or at least one epitope and at least one epitope cluster.

### Claim 19 (depends on 17)

The vector of claim 17, wherein the target-associated antigen is an antigen derived from or associated with a tumor or an intracellular parasite.

### Claim 20 (depends on 17)

A method of activating a T cell comprising contacting the vector of claim 17 with an APC and contacting said APC with a T cell.

### Claim 21

A substrate polypeptide comprising a housekeeping epitope wherein the housekeeping epitope can be liberated by immunoproteasome processing in a pAPC.
